HomeCompareCLSD vs O

CLSD vs O: Dividend Comparison 2026

CLSD yields 487.80% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CLSD wins by $50753.86M in total portfolio value
10 years
CLSD
CLSD
● Live price
487.80%
Share price
$0.41
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$50753.89M
Annual income
$36,168,404,531.85
Full CLSD calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.15
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,102.74
Full O calculator →

Portfolio growth — CLSD vs O

📍 CLSD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCLSDO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CLSD + O cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CLSD pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CLSD
Annual income on $10K today (after 15% tax)
$41,463.41/yr
After 10yr DRIP, annual income (after tax)
$30,743,143,852.07/yr
O
Annual income on $10K today (after 15% tax)
$449.12/yr
After 10yr DRIP, annual income (after tax)
$4,337.33/yr
At 15% tax rate, CLSD beats the other by $30,743,139,514.74/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CLSD + O for your $10,000?

CLSD: 50%O: 50%
100% O50/50100% CLSD
Portfolio after 10yr
$25376.96M
Annual income
$18,084,204,817.30/yr
Blended yield
71.26%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on O right now

CLSD
Analyst Ratings
5
Buy
3
Hold
Consensus: Buy
Altman Z
-48.3
Piotroski
2/9
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.7% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CLSD buys
0
O buys
0
No recent congressional trades found for CLSD or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCLSDO
Forward yield487.80%5.28%
Annual dividend / share$2.00$3.23
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.1%
Portfolio after 10y$50753.89M$34.2K
Annual income after 10y$36,168,404,531.85$5,102.74
Total dividends collected$49478.61M$20.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: CLSD vs O ($10,000, DRIP)

YearCLSD PortfolioCLSD Income/yrO PortfolioO Income/yrGap
1← crossover$59,480$48,780.49$10,818$608.16+$48.7KCLSD
2$334,811$271,167.03$11,787$741.68+$323.0KCLSD
3$1,784,770$1,426,522.08$12,946$911.00+$1.77MCLSD
4$9,016,553$7,106,848.63$14,345$1,127.94+$9.00MCLSD
5$43,202,271$33,554,559.81$16,056$1,409.05+$43.19MCLSD
6$196,483,123$150,256,693.49$18,171$1,777.83+$196.46MCLSD
7$848,895,486$638,658,543.63$20,820$2,268.21+$848.87MCLSD
8$3,487,095,949$2,578,777,778.75$24,188$2,929.90+$3487.07MCLSD
9$13,631,297,985$9,900,105,319.66$28,533$3,837.11+$13631.27MCLSD
10$50,753,893,375$36,168,404,531.85$34,235$5,102.74+$50753.86MCLSD

CLSD vs O: Complete Analysis 2026

CLSDStock

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Full CLSD Calculator →

OREIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this CLSD vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CLSD vs SCHDCLSD vs JEPICLSD vs KOCLSD vs MAINCLSD vs STAGCLSD vs ADCCLSD vs NNNCLSD vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.